Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release. Information in any press release may be superseded by more recent information we have disclosed in later press releases, filings with the Securities and Exchange Commission (“SEC”) or otherwise. Press releases may contain forward-looking statements based on the expectations of our management as of the date of the release. Actual results may materially differ based on several factors, including those described in the press releases and filings with the SEC.
| 2003 | 2002 | 2001 | 2000 | 1999 | Back to main index |
12/05/2000
11/16/2000
IDEC Pharmaceuticals Prices Public Offering
11/03/2000
11/01/2000
11/01/2000
10/16/2000
IDEC Pharmaceuticals Reports Third Quarter 2000 Results
08/07/2000
08/01/2000
07/18/2000
IDEC Pharmaceuticals Reports Second Quarter 2000 Results
07/17/2000
IDEC Pharmaceuticals Announces U.S. Rituxan Sales of $ 96.7 Million in Second Quarter, 2000
06/28/2000
05/23/2000
Preliminary and Updated Results of Four ZEVALIN Studies Presented at ASCO
04/20/2000
IDEC Pharmaceuticals Reports First Quarter 2000 Results
04/17/2000
04/12/2000
03/15/2000
IDEC Pharmaceuticals Announced Results of Phase I Study of Idec-114 Antibody in Psoriasis
02/22/2000
IDEC Pharmaceuticals Announces New Senior Vice President of Biopharmaceutical Sciences
02/03/2000
02/02/2000
IDEC Pharmaceuticals Reports Second Year of Profitability On Revenue Growth of 36 Percent
01/20/2000
| 2003 | 2002 | 2001 | 2000| 1999 | Back to main index |